Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/7/2023 | $35.00 | Neutral | UBS |
| 12/8/2022 | $65.00 → $40.00 | Overweight → Neutral | Piper Sandler |
| 11/18/2022 | $45.00 | Outperform | Raymond James |
| 8/25/2022 | $65.00 | Outperform | Credit Suisse |
| 2/4/2022 | $80.00 | Overweight | Piper Sandler |
| 1/25/2022 | $141.00 → $125.00 | Outperform | Oppenheimer |
| 8/10/2021 | $55.00 → $65.00 | Underperform | Credit Suisse |
| 8/5/2021 | $55.00 | Underperform | Credit Suisse |
10-Q - Fulgent Genetics, Inc. (0001674930) (Filer)
8-K - Fulgent Genetics, Inc. (0001674930) (Filer)
144 - Fulgent Genetics, Inc. (0001674930) (Subject)
Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ:FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting on June 2, 2024 in Chicago, Illinois.
Fulgent Genetics (NASDAQ:FLGT) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.32) by 96.88 percent. This is a 95.45 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $64.485 million which missed the analyst consensus estimate of $65.363 million by 1.34 percent. This is a 2.54 percent decrease over sales of $66.168 million the same period last year.
4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
Total Revenue of $71.7 million Core Revenue grows 9% year-over-year to $71.7 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2024. Third Quarter 2024 Results: Total Revenue of $71.7 million Core Revenue1 grew 9% year-over-year to $71.7 million GAAP loss of $14.6 million, or ($0.48) per share Non-GAAP income of $9.4 million, or $0.31 per share A
Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are scheduled to present at the following upcoming investor conferences: UBS Global Healthcare Conference on Tuesday, November 12th at 2:45 PM Pacific Time Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4th at 11:30 AM Eastern Time Live webcasts of the sessions will be available on the Investor Relations section of the Fulgent website at ir.fulgentgenetics.com. Replay of the webcasts will be accessible at the same location be
Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced it has been awarded a five-year contract by the U.S. Department of Veterans Affairs (VA) to provide hereditary cancer, pharmacogenetic and other genetic testing to Veterans. A leader in clinical molecular diagnostic testing, Fulgent has been periodically providing genetic testing services to the members of the VA since 2017. These have included both clinical and research-based services. This new award enables Fulgent to provide hereditary cancer tests to individuals with cancer or a family
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing. Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization. Dr. Wallar has more than 20 year
After promising results from first-in-man studies with its novel Neural Ice™ technology, the Massachusetts-based company will use the capital to initiate pivotal clinical studies in both chronic and acute pain indications CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Brixton Biosciences, a spin-out from Massachusetts General Brigham and a clinical stage life sciences company developing novel therapies for chronic and acute pain, today announced that it closed a Series B funding round of $33M. The round was led by Schooner Capital with notable participation by SV Health Investors, Sparta Group, Excelestar Ventures, PV Capital Management, and Catalyst Health Ventures.
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023. Mr. Kim currently serves as Chief Financial Officer of Fulgent Genetics (NASDAQ:FLGT), a full-service genomic testing company built around a foundational technology platform. He has held that position since February 2016 and led growth initiatives increasing revenues from $10M in 2015 to $990M in 2021, during the COVID-19 era. Mr. Kim has over 30 years working in accounting and finance, and over 15 years as a Chief Financial Officer of several public
SC 13D/A - Fulgent Genetics, Inc. (0001674930) (Subject)
SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)
SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)
UBS initiated coverage of Fulgent Genetics with a rating of Neutral and set a new price target of $35.00
Piper Sandler downgraded Fulgent Genetics from Overweight to Neutral and set a new price target of $40.00 from $65.00 previously
Raymond James initiated coverage of Fulgent Genetics with a rating of Outperform and set a new price target of $45.00
Total Revenue of $71.7 million Core Revenue grows 9% year-over-year to $71.7 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2024. Third Quarter 2024 Results: Total Revenue of $71.7 million Core Revenue1 grew 9% year-over-year to $71.7 million GAAP loss of $14.6 million, or ($0.48) per share Non-GAAP income of $9.4 million, or $0.31 per share A
Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent is
Total Revenue of $71.0 million Core Revenue grows 5% year-over-year to $70.2 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2024. Second Quarter 2024 Results: Total Revenue of $71.0 million Core Revenue1 grew 5% year-over-year to $70.2 million GAAP loss of $8.7 million, or ($0.29) per share Non-GAAP income of $4.7 million, or $0.15 per share